{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:21:28Z","timestamp":1782253288371,"version":"3.54.5"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Forty patients with MF were treated. Therapy consisted of lenalidomide 10 mg\/d (5 mg\/d if baseline platelet count &lt; 100 \u00d7 10<jats:sup>9<\/jats:sup>\/L) on days 1 through 21 of a 28-day cycle for six cycles, in combination with prednisone 30 mg\/d orally during cycle 1, 15 mg\/d during cycle 2, and 15 mg\/d every other day during cycle 3. Lenalidomide therapy was continued indefinitely in patients exhibiting clinical benefit. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The median follow-up was 22 months (range, 6 to 27). Responses were recorded in 12 patients (30%) and are ongoing in 10 (25%). The median time to response was 12 weeks (range, 2 to 32). According to the International Working Group for Myelofibrosis Research and Treatment consensus criteria, three patients (7.5%) had partial response and nine patients (22.5%) had clinical improvement durable for a median of 18 months (range, 3.5 to 24+). Overall response rates were 30% for anemia and 42% for splenomegaly. Moreover, 10 of 11 assessable responders who started therapy with reticulin fibrosis grade 4 experienced reductions to at least a score of 2. All eight JAK2<jats:sup>V617F<\/jats:sup>\u2013positive responders experienced a reduction of the baseline mutant allele burden, which was greater than 50% in four, including one of whom the mutation became undetectable. Grade 3 to 4 hematologic adverse events included neutropenia (58%), anemia (42%), and thrombocytopenia (13%). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The combination of lenalidomide and prednisone induces durable clinical, molecular, and pathologic responses in MF. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2009.22.6548","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T01:55:35Z","timestamp":1251770135000},"page":"4760-4766","source":"Crossref","is-referenced-by-count":129,"title":["Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis"],"prefix":"10.1200","volume":"27","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghi","family":"Manshouri","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia and Hematopathology, M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.346"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-8-929"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1856"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4299"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"},{"key":"B10","first-page":"112","author":"Shah N","year":"2008","journal-title":"Blood"},{"key":"B11","first-page":"112","author":"Pardanani A","year":"2008","journal-title":"Blood"},{"key":"B12","first-page":"112","author":"Moliterno A","year":"2008","journal-title":"Blood"},{"key":"B13","first-page":"112","author":"Verstovsek S","year":"2008","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1342"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3238"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412110"},{"key":"B17","first-page":"1027","volume":"91","author":"Abgrall JF","year":"2006","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.160"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"B21","first-page":"1128","volume":"90","author":"Thiele J","year":"2005","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404007"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.07.004"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.048496"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1323"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(04)00666-X"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061292"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041668"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2360"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4169"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3374"},{"key":"B36","first-page":"1454","volume":"89","author":"Arora B","year":"2004","journal-title":"Haematologica"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2009.22.6548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:33:31Z","timestamp":1653521611000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2009.22.6548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":36,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2009,10,1]]}},"alternative-id":["10.1200\/JCO.2009.22.6548"],"URL":"https:\/\/doi.org\/10.1200\/jco.2009.22.6548","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,1]]}}}